1
Antonio J Grillo López: Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody. IDEC Pharmaceuticals Corporation, Robin L Teskin, September 24, 2002: US06455043 (127 worldwide citation)

New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise in particular administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkins lymphomas.


2
Antonio J Grillo López: Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody. Biogen Idec, Wendy Lee, Ginger R Dreger, Arnold & Porter, December 11, 2012: US08329172 (36 worldwide citation)

New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise in particular administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkins lymphomas.


3
Grillo Lopez Antonio: Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody. Biogen Idec, October 1, 2008: EP1974747-A1 (4 worldwide citation)

New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise in particular administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkins lymphomas.


4
Grillo López Antonio: Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody. Idec Pharmaceuticals Corporation, Grillo López Antonio, GESS E Joseph, February 24, 2000: WO/2000/009160 (1 worldwide citation)

New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise in particular administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkins lymphomas.


5
Antonio J Grillo Lopez: Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody. Biogen, Ginger R Dreger, October 30, 2018: US10113000

New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise, in particular, administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkin's lymphomas.


6
Grillo Lopez Antonio: Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody. Biogen Idec, July 23, 2008: EP1946775-A2

New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise in particular administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkins lymphomas.


7
Grillo Lopez Antonio: Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody. Idec Pharma, July 4, 2001: EP1112084-A1

New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise in particular administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkins lymphomas.


8
GRILLO LOPEZ ANTONIO: [fr] Polythérapies pour lymphomes B comprenant ladministration dun anticorps anti-CD20, [de] Kombinationstherapien für B-Zellen-Lymphome mit Verabreichung eines Anti-CD20-Antikörpers, [en] Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody. BIOGEN IDEC, December 22, 2010: EP2263693-A1

[en] New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise in particular administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkins lymphomas.


9
GRILLO LOPEZ ANTONIO: [fr] Polythérapies pour lymphomes B comprenant ladministration dun anticorps anti-CD20, [de] Kombinationstherapien für B-Zellen-Lymphome mit Verabreichung eines Anti-CD20-Antikörpers, [en] Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody. BIOGEN IDEC, January 19, 2011: EP2275136-A1

[en] New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise in particular administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkins lymphomas.


10
GRILLO LOPEZ ANTONIO: [fr] Polythérapies pour lymphomes B comprenant ladministration dun anticorps anti-CD20, [de] Kombinationstherapien für B-Zellen-Lymphome mit Verabreichung eines Anti-CD20-Antikörpers, [en] Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody. BIOGEN IDEC, December 15, 2010: EP2260866-A1

[en] New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise in particular administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkins lymphomas.